drugset / Trial / NCT00660985

Pharmacokinetic Study to Compare the Systemic Exposure of Differin® Gel, 0.3% or Differin® Gel, 0.1%

NCT00660985

Phase 4 Completed 51 enrolled Galderma R&D
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 4 commitment pharmacokinetic study to determine systemic exposure to adapalene.

Timeline

Start
2008-05
Primary completion
2008-08
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adapalene Other / unclassified 0.1 % Topical
Comparator Adapalene Other / unclassified 0.3 % Topical

Indications